– USA, CA – Varian (NYSE:VAR), today announced that Jeffrey R. Balser, MD, PhD, president and chief executive officer at Vanderbilt University Medical Center and dean of Vanderbilt University School of Medicine, has been appointed to the Varian Board of Directors, effective October 1, 2018.
“We are very pleased that Jeff Balser has joined the Varian board,” said R. Andrew Eckert, chairman of Varian’s Board of Directors. “Jeff brings to Varian a diverse and proven skill set as a physician, scientist and businessman. We look forward to his contributions in assisting Varian’s transformation from the leader in radiation therapy to the leader in cancer care solutions.”
“Varian has a well-earned reputation as a strong mission-driven company developing and delivering innovative cancer care solutions,” said Dr. Balser. “I look forward to working with my fellow Board members and the Varian team to continue the company’s growth efforts in creating a world without the fear of cancer.”
Dr. Balser, 56, has served as the president and CEO of Vanderbilt University Medical Center since 2016 and the dean of Vanderbilt University School of Medicine since 2008. During this time, he has led the Medical Center through a period of increased service volume with major inpatient expansions of the children’s hospital and the adult critical care areas. Dr. Balser earned his medical and PhD degrees from Vanderbilt University and completed his residency and fellowship training at The Johns Hopkins Hospital. Additionally, he earned a Bachelor of Science degree in Engineering from Tulane University.
Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world.
For more information : http://www.varian.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.